Skip to main content
. 2021 Nov 22;11:762288. doi: 10.3389/fonc.2021.762288

Figure 3.

Figure 3

Forest plots of the pooled risk ratios for discontinuation rate (A) and toxic death (B) between doxorubicin/adriamycin plus ifosfamide combination chemotherapy and doxorubicin/adriamycin monotherapy.